Tag: AML
ncRNA | Free Full-Text | Small Nucleolar (Sno)RNA: Therapy Lays in Translation
2.1. Specificity SnoRNAs are ubiquitous and highly abundant RNAs [21,28]. So, how can one target the malignant cell with little to no harm to healthy cells? Recent publications have demonstrated that some rRNA modifications occur in sub-stoichiometric levels [10,29]. This finding has overturned the notion that all rRNA modifications are…
Assessing Methylation-Based Sequencing as a Risk-Stratifying Tool in MDS
Methylation-based sequencing appears to be a viable risk-assessment tool for myelodysplastic syndromes (MDS), according to a study presented at the 2023 American Society of Clinical Oncology Annual Meeting. “MDS risk stratification is key for [making] optimal treatment decisions. DNA methylation is associated with MDS biology due to frequent somatic mutations…
A familial SAMD9 variant present in pediatric myelodysplastic syndrome
Cold Spring Harb Mol Case Stud. 2023 Apr; 9(2): a006256. ,1,2 ,1,2 ,1,2 ,2,3 ,4 and 1,2 Mahvish Q. Rahim 1Pediatric Hematology Oncology, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA; 2Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, USA; April Rahrig 1Pediatric Hematology Oncology,…
Abnormal ressource usage with PyTorch’s DataLoader and as_mount
I see no post about this problem but I have a training speed issue using as_mount for the Blob Storage with DataLoader in PyTorch. The job is just downloading images (by batches only used once) from the blob (by mounting it : data = datastore.path(“./”).as_mount()) and training a neural net…
Invivoscribe, Complete Genomics partner to develop NGS tests for cancer research, detection
Invivoscribe and Complete Genomics said Friday that they are partnering to develop and commercialize biomarker tests. Under the terms of the deal, Invivoscribe will be responsible for the development of biomarker tests, including test controls and associated bioinformatics software. The tests will run on Complete Genomics’ next-generation sequencing (NGS) platforms….
Invivoscribe Partners with Complete Genomics to Develop and Commercialize Biomarker Tests for Oncology and Cancer Research
SAN DIEGO and SAN JOSE, Calif. , June 2, 2023 /PRNewswire/ — Invivoscribe and Complete Genomics announced today that they had entered a partnership to develop and commercialize biomarker tests on Complete Genomics’ NGS platforms. The territory is worldwide, and the field is oncology and cancer research. Under the terms…
Blood Test Detects Residual Disease For Adults With AML in Remission Prior to Bone Marrow Transplant
In 2020, there were more than 73,000 people living with acute myeloid leukemia (AML) in the United States. Approximately 31% of those with AML are estimated to survive 5 or more years after their diagnosis.1 Although a bone marrow transplant may increase that 5-year survival rate, the efficacy of the…
Invivoscribe Announces Updated Reimbursement for the LeukoStrat CDx FLT3 Mutation Assay to Select Newly Diagnosed FLT3-ITD Positive AML Patients Eligible for VANFLYTA in Japan APAC – English USA – English
SAN DIEGO, May 26, 2023 /PRNewswire/ — Invivoscribe is pleased to announce that their LeukoStrat CDx FLT3 Mutation Assay® has received updated reimbursement by Japan’s Ministry of Health, Labor and Welfare (MHLW) to aid in the selection of patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML) who may be…
Invivoscribe Announces Updated Reimbursement for the LeukoStrat CDx FLT3 Mutation Assay to Select Newly Diagnosed FLT3-ITD Positive AML Patients Eligible for VANFLYTA in Japan, Business News
SAN DIEGO, May 26, 2023 /PRNewswire/ — Invivoscribe is pleased to announce that their LeukoStrat CDx FLT3 Mutation Assay® has received updated reimbursement by Japan’s Ministry of Health, Labor and Welfare (MHLW) to aid in the selection of patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML) who may…
2023-05-25 | NYSE:BMY | Press Release
Results from Phase 3 COMMANDS study, selected for ASCO’s official press program,show nearly twice as many patients treated with Reblozyl achieved superior transfusion independence with concurrent hemoglobin increase vs. epoetin alfa, including in clinically relevant subgroups Reblozyl demonstrated a durable response, with nearly 2.5 years median transfusion independence, 1 year…
SELLAS Life Sciences to Present Phase 3 REGAL Trial in Progress Poster at 2023 ASCO Annual Meeting
/EIN News/ — NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that a trial in progress poster for…
SELLAS Life Sciences to Present Phase 3 REGAL Trial in
NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that a trial in progress poster for the Phase 3…
Voruciclib/Venetoclax Shows Early Disease Control in Acute Myeloid Leukemia
Treatment with voruciclib both with and without venetoclax (Venclexta) appears to be tolerable and efficacious for patients with relapsed/refractory acute myeloid leukemia (AML) and B-cell malignancies, according to a press release by MEI Pharma on early findings from a phase 1 study (NCT03547115). Voruciclib is an oral CDK9 inhibitor, hypothesized…
Unmet Needs in Diffuse Large B-Cell Lymphoma
Transcript: Andre H. Goy, MD: We cure a very large fraction of patients with large cell lymphoma, and CAR [chimeric antigen receptor] T-cell therapy now cures a fraction of the patients. In large cell lymphoma, we probably cure close to 40% with anti-CD19 CAR T-cell therapy. So as you mentioned,…
NK Cell Therapy Pipeline Insight
PRESS RELEASE Published May 24, 2023 DelveInsight’s, “NK Cell Therapy Pipeline Insight 2023” report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in the NK Cell Therapy pipeline landscape. It covers the NK Cell Therapy pipeline drug profiles, including NK Cell Therapy clinical trials and nonclinical stage products….
The roles and implications of RNA m6A modification in cancer
Huang, H., Weng, H. & Chen, J. m6A modification in coding and non-coding RNAs: roles and therapeutic implications in cancer. Cancer Cell 37, 270–288 (2020). Article CAS PubMed PubMed Central Google Scholar Qing, Y., Su, R. & Chen, J. RNA modifications in hematopoietic malignancies: a new research frontier. Blood 138,…
Pre-Transplant DNA Sequencing Suggests Association Between Persistence of Most-Common AML Variants and Poorer Outcomes in Patients with AML
Rates of relapse and worse survival were associated with persistent FLT3-ITD or NPM1 variants prior to allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia. Detection by DNA sequencing of persistent FLT3-ITD or NPM1 variants – the two most common AML variants – in blood ahead of allogeneic hematopoietic cell transplantation (allo-HCT)…
SC-DARIC33 Demonstrates Potential Next-Generation Approach in AML
Image Credit: © AkuAku [stock.adove.com] Infusions of SC-DARIC33, a chimeric antigen receptor (CAR) T-cell therapy, were well tolerated and did not show dose-limiting toxicities in patients with relapsed or refractory acute myeloid leukemia (AML) according to findings from the preliminary correlative analysis of the ongoing phase 1 PLAT-08 trial (NCT05105152).1…
Senti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Senti Biosciences, Inc. Five presentations showcase the modularity and applicability of Senti’s Gene Circuit technology in NK cells, T cells, AAVs, iPSCs, and macrophages SOUTH SAN FRANCISCO, Calif., May 20, 2023 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies…
Rituximab Regimen Yields Sustained Survival in Geriatric Mantle Cell Lymphoma
The combination of rituximab (Rituxan), bendamustine (Bendeka), and low-dose cytarabine (R-BAC) without maintenance therapy maintained clinical efficacy after longer follow-up in a cohort of elderly patients with previously untreated mantle cell lymphoma (MCL), according to new findings from the phase 2 RBAC500 clinical trial (NCT01662050) published recently in Blood Advances….
GILEAD AND KITE ONCOLOGY TO SHOWCASE ADVANCES ACROSS THE PIPELINE AIMING TO ADDRESS UNMET NEEDS IN CANCER CARE AT ASCO 2023
GILEAD AND KITE ONCOLOGY TO SHOWCASE ADVANCES ACROSS THE PIPELINE AIMING TO ADDRESS UNMET NEEDS IN CANCER CARE AT ASCO 2023 – Data Across 30 Abstracts Reinforce Leadership in Metastatic Breast Cancer and Demonstrate Breadth of Pipeline Across Lung, Haematologic, Genitourinary, Gastrointestinal, Gynaecological and Other Solid Tumours – –…
Iterion Therapeutics Announces the Initiation of a Phase 1 Clinical Trial for Tegavivint in Patients with c-Myc-overexpressing Relapsed or Refractory Large B-Cell Lymphomas
HOUSTON, May 16, 2023 /PRNewswire/ — Iterion Therapeutics, a leading biopharmaceutical company dedicated to the development of innovative treatments for cancer, announced today its collaboration in a Phase 1 clinical trial for tegavivint in patients with relapsed or refractory c-Myc-overexpressing large B-cell lymphomas. The first patient has been enrolled to…
Phase 3 Study of DFP-10917 in the R/R AML Patients Shall Be Done with the 1st Interim Analysis for NDA Approval.
150 patients have been enrolled at the multi-clinical centers in US to the Phase 3 randomized trial of DFP-10917 vs non-intensive reinduction (LoDAC, Azacytidine, Decitabine, Venetoclax combo-regimens) or intensive reinduction (high and intermediate dose of Cytarabine regimens) in the 2nd, 3rd, or 4th salvage of AML and the 1st interim…
Invivoscribe Announces IVDR Approval of the LeukoStrat CDx FLT3 Mutation Test
69 11.05.2023 – 16:59 Invivoscribe, Inc. San Diego (ots/PRNewswire) SAN DIEGO, May 11, 2023 /PRNewswire/– “We are pleased to announce today that the LeukoStrat® CDx flt3 -Invivoscribe’s mutation test has been approved by BSI (Netherlands) and EMA as a Class C CDx test that meets the stringent new IVDR requirements…
Invivoscribe Announces IVDR Approval of the LeukoStrat CDx FLT3 Mutation Assay
SAN DIEGO, May 11, 2023 /PRNewswire/ — “Today we are pleased to announce that Invivoscribe’s LeukoStrat® CDx FLT3 Mutation Assay has been approved by BSI (Netherlands) and the EMA as a Class C CDx assay, meeting the stringent new IVDR (Regulation (EU) 2017/746) requirements. Invivoscribe is one of the first companies…
Senti Bio Announces First Quarter 2023 Results and Pipeline
– New preclinical data at AACR supports SENTI-202 as a potential first-in-class logic gated CAR-NK cell therapy; remains on track for IND submission and clearance in 2H 2023 – – Initial collaboration data with BlueRock and Spark to be presented at ASGCT, validating that Senti’s Gene Circuit enabled cell platform…
Active Research on Uproleselan in Acute Myeloid Leukemia
Brian A. Jonas, MD, associate professor of medicine at UC Davis Health in Sacramento, California, discusses studies investigating the use of uproleselan for the treatment of patients with acute myeloid leukemia (AML). Transcript: 0:08 | been a drug developed to target the e-selectin ligand interaction, it’s a so-called e-selecting antagonist and…
python – Why does my training confusion matrix in h2o AutoML only shows 10k total cases instead of 200k
I am currently using h2o autoML to train a model on a binary classification problem. I have a train (70% ~200k rows), valid (10% ~30k rows), test (10% ~30k rows) and blend (10% ~30k rows) datasets all coming from the time sensitive splitting of the original dataset (~300k rows). When…
Epigenetic priming improves salvage chemotherapy in diffuse large B-cell lymphoma via endogenous retrovirus-induced cGAS-STING activation | Clinical Epigenetics
5-Azacytidine pretreatment resensitizes cisplatin-resistant DLBCL cell lines to cisplatin to varying degrees A platinum-based anti-neoplastic agent is an essential component of salvage regimens for aggressive lymphomas, for example, rituximab, gemcitabine, dexamethasone, and cisplatin (R-GDP) for relapsed/refractory DLBCL and Hodgkin lymphoma [21]. As a single agent in humans, cisplatin is administered…
Biomea Fusion Reports First Quarter 2023 Financial Results
Reported initial positive clinical data from first two cohorts of Phase II of ongoing Phase I/II study (COVALENT-111) of BMF-219, Biomea’s lead investigational, orally administered covalent menin inhibitor, as a novel, potentially disease-modifying treatment for patients with type 2 diabetes Continued enrolling four liquid tumor cohorts in ongoing Phase I…
Patient-derived iPSCs faithfully represent the genetic diversity and cellular architecture of AML
Dr Eirini Papapetrou speaks to ecancer about her study which found that patient-derived iPSCs faithfully represent the genetic diversity and cellular architecture of human acute myeloid leukaemia. This study created a reprogramming method called “Complete Capture of Mutational Burden” (CCoMB). This method combines comprehensive genetic characterisation of the starting sample…
Applications of single-cell RNA sequencing in drug discovery and development
DiMasi, J. A., Grabowski, H. G. & Hansen, R. W. Innovation in the pharmaceutical industry: new estimates of R&D costs. J. Health Econ. 47, 20–33 (2016). Article PubMed Google Scholar Wouters, O. J., McKee, M. & Luyten, J. Estimated research and development investment needed to bring a new medicine to…
Actinium Highlights Successful Administration of Targeted Radiotherapy Iomab-B Across Various BMT Centers with Ease and Without Increasing Radiation Exposure Risks to Treating Nursing Staff in the Pivotal Phase 3 SIERRA Trial at the 48th Annual Oncology Nursing Society (ONS) Congress
– 24 leading bone marrow transplant (BMT) centers that perform over 30% of transplants in the U.S. participated in the SIERRA trial that enrolled patients with active relapsed or refractory acute myeloid leukemia – Demonstration of rapid ability and ease of adoption for Iomab-B infusions at SIERRA sites NEW YORK,…
Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results
NEW YORK – Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (‘Actinium’ or the ‘Company’), a leader in the development of targeted radiotherapies, today announced that the positive results from the pivotal Phase 3 SIERRA Trial of Iomab-B were presented in an oral presentation at the European Society for Blood and Marrow…
Uproleselan Combinations Contribute to Robust Investigational Profile in AML
Michael Andreeff, MD, PhD The E-selectin inhibitor uproleselan (GMI-1271) has shown preliminary efficacy in patients with acute myeloid leukemia (AML), and E-selectin could represent one of several novel targets for treatment of this patient population, according to Michael Andreeff, MD, PhD. Previously, a phase 1/2 trial (NCT02306291) investigating uproleselan plus…
2023-04-27 | NYSEAM:ATNM | Press Release
– EBMT oral presentation builds awareness for Iomab-B and the SIERRA trial results with the European transplant community that performs twice as many transplants compared to the U.S. – Iomab-B enabled unprecedented 100% bone marrow transplant access and engraftment with 75% post-BMT CR rate in patients with active, relapsed or…
Actinium Pharma (ATNM) Announces Positive Pivotal Phase 3 SIERRA Trial Results of Iomab-B Showcased to the European Transplant Community in Oral Presentation
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here. Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”), a leader in the development of targeted radiotherapies, today announced that the positive results from the pivotal Phase 3…
Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results of Iomab-B Showcased to the European Transplant Community in Oral Presentation at the European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting
– EBMT oral presentation builds awareness for Iomab-B and the SIERRA trial results with the European transplant community that performs twice as many transplants compared to the U.S. – Iomab-B enabled unprecedented 100% bone marrow transplant access and engraftment with 75% post-BMT CR rate in patients with active, relapsed or…
Actinium Pharma Announces Positive Pivotal Phase 3 SIERRA Trial Results of Iomab-B Showcased to the European Transplant Community in Oral Presentation
Actinium Pharmaceuticals (NYSE:), Inc. (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”), a leader in the development of targeted radiotherapies, today announced that the positive results from the pivotal Phase 3 SIERRA Trial of Iomab-B were presented in an oral presentation at the European Society for Blood and Marrow Transplantation (EBMT)…
Ceftriaxone resistant Salmonella enterica serovar Paratyphi A identified in a case of enteric fever: first case report from Pakistan | BMC Infectious Diseases
Typhoid GBD, Paratyphoid C. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Infect Dis. 2019;19(4):369–81. Article Google Scholar Arndt MB, Mosites EM, Tian M, Forouzanfar MH, Mokhdad AH, Meller M, Ochiai RL, Walson JL. Estimating the burden of…
FDA Extends Review Period for Quizartinib for Adults With FLT3-ITD-Positive AML
Note: This article has been updated to reflect the correct revised PDUFA date. FDA has added 3 months to the review timeline for quizartinib, an investigational therapy for the treatment of adult patients with newly diagnosed FLT3-ITD-positive acute myeloid leukemia (AML), an aggressive form of the blood cancer. Daiichi Sankyo…
I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China
GAITHERSBURG, Md. and SHANGHAI, April 24, 2023 /PRNewswire/ — I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the first patient in a Phase 3 registrational trial (ClinicalTrials.gov Identifier: NCT05709093) in China for patients with higher-risk myelodysplastic syndrome…
IDMC Recommends Continuation of REGAL Trial of Galinpepimut-S in AML
Angelos Stergiou, MD, ScD hc An independent data monitoring committee (IDMC) has recommended that the phase 3 REGAL trial (NCT04229979) examining galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML) continue as planned without modifications.1 The recommendation follows a positive prespecified risk-benefit assessment of unblinded data from the study. The…
NK Cell Therapy Pipeline Booms as 100+ Companies likely to Enter in the Treatment Domain
PRESS RELEASE Published April 18, 2023 DelveInsight’s, “NK Cell Therapy Pipeline Insight 2023,” report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in the NK Cell Therapy pipeline landscape. It covers the NK Cell Therapy pipeline drug profiles, including NK Cell Therapy clinical trials and nonclinical stage products….
Patient-Derived iPSCs Faithfully Represent the Genetic Diversity and Cellular Architecture of Human Acute Myeloid Leukemia
doi: 10.1158/2643-3230.BCD-22-0167. Online ahead of print. Andriana G Kotini # 1 2 3 4 , Saul Carcamo # 1 5 , Nataly Cruz-Rodriguez # 1 2 3 4 , Malgorzata Olszewska 1 2 3 4 , Tiansu Wang 1 2 3 4 , Deniz Demircioglu …
Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting | DNA RNA and Cells
Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting Details Category: DNA RNA and Cells Published on Tuesday, 18 April 2023 10:14 Hits: 247 — CB-012 genome-edited armoring strategy significantly reduced tumor burden and improved overall survival in AML…
Positive Results for SELLAS Life Sciences Phase 3 REGAL Study for GalinpepimutS in AML
SELLAS Life Sciences Group, Inc. has announced that the Independent Data Monitoring Committee (IDMC) overseeing the Phase 3 REGAL study for galinpepimut-S (GPS) in acute myeloid leukemia (AML) has given the green light for the trial to continue as planned without modifications. This is a positive development for the company,…
Human Acute Myeloid Leukemia Reportedly Closely Mimicked for First Time by Transformative Models
Tisch Cancer Center scientists report that they have developed novel models of the deadliest blood cancer, acute myeloid leukemia (AML), creating a “transformative resource” to study this cancer and eventually its drug response and drug resistance, according to research presented at the annual meeting of the American Association of Cancer…
Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting
Caribou Biosciences, Inc. — CB-012 genome-edited armoring strategy significantly reduced tumor burden and improved overall survival in AML xenograft models — — CB-012 IND-enabling studies ongoing; IND submission in r/r AML planned for H2 2023 — BERKELEY, Calif., April 17, 2023 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a…
Senti Bio to Participate in Upcoming Investor Conferences
Senti Biosciences, Inc. SOUTH SAN FRANCISCO, Calif., April 14, 2023 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced its participation at the following investor conferences: Bank of America 2023 Global Healthcare…
Abstract LB130: Single-cell multiomics analysis of myelodysplastic syndrome predicts clinical response to DNA methylation inhibitor therapy | Cancer Research
Epigenetic alterations, such as DNA methylation aberrations, are a hallmark of human cancer. This observation has led to the assessment of hypomethylating agents (HMAs) as potential drugs to treat oncological patients, being considered the clinical approval of these pharmacological compounds in the therapy of myeloid malignancies as one of the…
Function Oncology Launches With $28M, Seeks to Transform Precision Oncology With CRISPR
NEW YORK – Function Oncology launched on Wednesday with $28 million in recently raised Series A funds and a CRISPR-Cas9 platform, which it hopes will help oncologists tailor patients’ treatments based on the function of their individual cancer genes. The San Diego-based firm is unveiling the first validation data of…
Automated Machine Learning with Python: A Case Study
Image by Author In today’s world, all organizations want to use Machine learning to analyze the data they generate daily from the users. With the help of a machine or deep learning algorithms, they can analyze the data. Afterwards, they can make the prediction of testing data in the…
Pacylex Pharmaceuticals Selected as One of Sixteen Canadian Startup Companies to Present at Sweet Biopharma Day 2023
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here. Edmonton, Alberta, Canada/April 10, 2023- Pacylex Pharmaceuticals today announced it will be presenting at two exclusive life science startup events in Canada in April, spotlighting its emergence as one of the premier…
DNA Sequencing Testing Used to Detect Residual AML Prior to Transplant
The use of high sensitivity DNA sequencing tests to measure residual disease in AML could improve identification of patients at risk for relapse or death. “In acute myeloid leukemia (AML), the association between measurable residual disease (MRD)—leukemic cells remaining in a patient during clinical remission but not detectable by standard…
Targeting Oncogenic Fusions to Combat Pediatric Cancer Cells
Computational biologists at St. Jude categorized and identified the mechanism underlying oncogenic fusions in pediatric cancer cells. The researchers showed in mice that targeting oncogenic fusions that drive cancer with genome editing tools such as CRISPR has the potential to cure certain tumors. The findings were published in Nature Communications in…
DNA Sequencing Prior to HCT Identifies Patients at Risk of Poor AML Outcomes
In patients with acute myeloid leukemia (AML) in first remission, the persistence of certain DNA variants related to measurable residual disease (MRD) prior to allogeneic hematopoietic cell transplant (HCT) was associated with post-HCT relapse and worse survival outcomes in a recent study. The findings, published in JAMA, suggest that the…
High-resolution Nanopore methylome-maps reveal random hyper-methylation at CpG-poor regions as driver of chemoresistance in leukemias
Nanopore reads coupled to a novel computational method extends analyses of differential methylation to sparse CpGs (outside CpG islands) We analyzed tumor samples at diagnosis (T) and relapse (R) from three AML patients (UD5, UD10 and AML2) who received standard chemotherapy and relapsed with chemoresistant disease (supplementary Table 1). DNA from…
Noncatalytic regulation of 18S rRNA methyltransferase DIMT1 in acute myeloid leukemia
Yulia Gonskikh1,6, Julian Stoute1,2,6, Hui Shen1,6, Krista Budinich3,4,5, Bianca Pingul1,2, Kollin Schultz1,2, Heidi Elashal1,2, Ronen Marmorstein1,2, Junwei Shi3,4,5 and Kathy Fange Liu1,2 1Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA; 2Graduate Group in Biochemistry and Molecular Biophysics, Perelman School of Medicine, University…
St. Jude computational biologists characterize the full spectrum of oncogenic fusions in pediatric cancer
The scientific foundation needed to work on curing a class of cancer-causing mutations is here, in the form of a tool from St. Jude Children’s Research Hospital. Computational biologists at St. Jude comprehensively categorized and identified the mechanism underlying oncogenic fusions in pediatric cancer cells. Oncogenic fusions are mutations that…
Deep genomic characterization highlights complexities and prognostic markers of pediatric acute myeloid leukemia
FG spectrum in pediatric AML patients A combinatorial approach, including conventional and next-generation sequencing (NGS)-based assays, was employed to profile the FG landscape (see Methods). FG analysis was feasible for 138 patients (94% of the entire cohort, Supplementary Data 1) from whom suitable testing materials were available. The most common FGs…
CRISPR & Cas Genes Market Will Registered 17.03% Growth Globally
The CRISPR & Cas Genes market growth is driven by increasing number of clinical trials associates with CRIPR technology and rising of development of novel technologies. The CRISPR & Cas genes market revenue will reach at USD 8.96 billion by 2030 with a CAGR of around 17.03% from 2022 to…
Postdoctoral Fellow – Leukemia (computational/bioinformatics) job with University of Texas MD Anderson Cancer Center
We are seeking a Postdoctoral Fellow with computational/bioinformatics background to work on functional and immunogenomic profiling focusing on leukemia. Our lab conducts single cell, bulk, spatial and CRISPR profiling of AML and immune cells. Our goal is to apply innovative functional genomics, immunogenomics, and bioinformatics approaches to better understand leukemogenesis,…
Advance on engineering of bacteriophages
Introduction Bacteriophage (phage) is a class of widespread viruses exclusively infecting bacteria, playing a key role in ecosystems.1–3 Since phages were discovered over a hundred years ago, many techniques and reagents, such as DNA polymerase, restriction endonuclease, ligase, and CRISPR/Cas system, have been developed from phages, which have together accelerated…
Research Assistant/Research Associate in Inflammation and Computational Biology job with KINGS COLLEGE LONDON
Job description This is an exciting opportunity to be a key member of a team that is researching the genomic origins of inflammatory disease and myeloid cancers. We are studying clonal haematopoiesis or CHIP, where individuals acquire mutations in blood cells without apparent blood disease, and these mutations occur in…
As Use of Large Cancer Panels and Whole-Genome Sequencing Expands, Illumina Plans to Future-Proof NGS Interpretation and Reporting
Illumina is releasing a new cloud-based, customizable platform that enables tertiary analysis for clinical NGS data, which the company says will streamline interpretation and reporting for a diverse range of application areas. Through application programming interface (API)-based calls, the platform will allow labs to scale up their NGS applications and…
Dual target therapy reduces DLBCL recurrence
Dual target therapy reduces DLBCL recurrence Non-Hodgkin’s lymphoma is one of the ten most common cancers in Hong Kong, and diffuse large B-cell lymphoma (DLBCL) is the most common type, accounting for about 30% to 40% of cancers. Although the traditional treatment has achieved good results in the past 20…
Biomea Fusion Reports Fourth Quarter and Full Year 2022
Expanded clinical development footprint of BMF-219, the company’s lead investigational, orally administered, covalent menin inhibitor, to eight liquid and solid tumor indications and type 2 diabetes across three ongoing clinical trials COVALENT-101 (Phase I study) enrolling four liquid tumor cohorts, each focused on distinct patient subsets of acute lymphocytic and…
100+ Active Companies working to Develop 185+ Pipeline Therapies for NK Cell Therapy Treatment
PRESS RELEASE Published March 23, 2023 DelveInsight’s, “NK Cell Therapy Pipeline Insight 2023,” report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in the NK Cell Therapy pipeline landscape. It covers the NK Cell Therapy pipeline drug profiles, including NK Cell Therapy clinical trials and nonclinical stage products….
Creating sample groups from a combination of genes for survival analysis
This is the post/tutorial where Dr Kevin Blighe showed how to perform survival analysis with gene here in this he showed how to use single gene as predictor and create groups based on expression and classify them as mid or high or low. Now How to do the same with…
FDA Grants Orphan Drug Designation to EP0042 for AML
The FDA has granted orphan drug designation to the investigational dual FLT-3 and Aurora kinase inhibitor EP0042 for the treatment of pretreated acute myeloid leukemia (AML), according to a press release from Ellipses Pharma.1 “The designation is an important milestone in the development of EP0042 and underscores the work we…
10 immunotherapy companies making waves in 2023
Immunotherapy has been widely studied in cancer treatment research, ever since William Coley, who is regarded as the father of immunotherapy, first attempted to leverage the immune system for oncological therapy in 1891. Soon enough, the transformative power of cancer vaccines were observed where tumor-specific antigens triggered antitumor immune responses….
Bea Stollnitz – Training and deploying your PyTorch model in the cloud with Azure ML
Introduction You’ve been training your PyTorch models on your machine, and getting by just fine. Why would you want to train and deploy them in the cloud? Training in the cloud will allow you to handle larger ML models and datasets than you could train on your development machine. And…
Astellas menopause study meets endpoints, leukemia drug doesn’t
There was good and bad news this week from Japanese company Astellas Pharma Inc. as one of its trials yielded positive results, while another didn’t meet its endpoints. Astellas Pharma announced pivotal phase 3 results for its study of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment…
Genomic Alterations, Gene Expression Profiles and Functional Enrichment of Normal-Karyotype Acute Myeloid Leukaemia Based on Targeted Next-Generation Sequencing
. 2023 Feb 22;15(5):1386. doi: 10.3390/cancers15051386. Affiliations Expand Affiliations 1 Department of Haematology, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, Kubang Kerian 16150, Malaysia. 2 Clinical Haematology Referral Laboratory, Haematology Department, Hospital Ampang, Ministry of Health Malaysia, Ampang 68000, Malaysia. 3 Department of Biomedical Science, College of Health…
Scientists identify the cause of leukemia in people with trisomy 21
People with a third copy of chromosome 21, known as trisomy 21, are at high risk of developing Acute Myeloid Leukaemia (AML), an aggressive form of blood cancer. Scientists led by the Department of Paediatrics at University Hospital Frankfurt have now identified the cause: although the additional chromosome 21 leads…
Caribou Biosciences Reports Fourth Quarter and Full Year
— CB-010 ANTLER Phase 1 trial in r/r B-NHL ongoing with update planned for H2 2023 — — CB-011 CaMMouflage Phase 1 trial in r/r MM recruiting patients at dose level 1 — — CB-012 IND-enabling studies initiated; IND submission in r/r AML planned for H2 2023 — — $317.0…
QIAGEN (QGEN) to Develop CDx Test for TIBSOVO With New Pact
QIAGEN N.V.QGEN recently announced that it has entered into a strategic partnership with Servier. The agreement is intended to develop a companion diagnostic test for TIBSOVO — an isocitrate dehydrogenase-1 or IDH1 inhibitor indicated for treating the blood cancer acute myeloid leukemia or AML. For investors’ note, QIAGEN has master…
GDCquery error downloading TARGET-AML data
Hello there, I’m trying to download TARGET-AML data via GDCquery: library(TCGAbiolinks) query_target <- GDCquery(project = “TARGET-AML”, data.category = “Transcriptome Profiling”, data.type = “Gene Expression Quantification”, workflow.type = “STAR – Counts”) And I got this error: Warning messages: 1: In open.connection(con, “rb”) : URL ‘https://api.gdc.cancer.gov/files/?pretty=true&expand=cases,cases.samples.portions.analytes.aliquots,cases.project,center,analysis,cases.samples&size=10246&filters=%7B%22op%22:%22and%22,%22content%22:[%7B%22op%22:%22in%22,%22content%22:%7B%22field%22:%22cases.project.project_id%22,%22value%22:[%22TARGET-AML%22]%7D%7D,%7B%22op%22:%22in%22,%22content%22:%7B%22field%22:%22files.data_category%22,%22value%22:[%22Transcriptome%20Profiling%22]%7D%7D,%7B%22op%22:%22in%22,%22content%22:%7B%22field%22:%22files.data_type%22,%22value%22:[%22Gene%20Expression%20Quantification%22]%7D%7D,%7B%22op%22:%22in%22,%22content%22:%7B%22field%22:%22files.analysis.workflow_type%22,%22value%22:[%22STAR%20-%20Counts%22]%7D%7D]%7D&format=JSON’: Timeout of 60 seconds was reached…
Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Entered into a €40 million credit facility with the European Investment Bank and closed an approximatively $25 million follow-on equity offering to support Cellectis’ research, development and innovation activities Positive preliminary clinical data from Phase 1 BALLI-01 study (evaluating UCART22) for patients with r/r B-cell ALL presented…
Blood-Based MRD Testing Identifies AML Patients at Risk of Relapse After Stem Cell Transplant
NEW YORK – Using DNA sequencing to detect measurable residual disease (MRD) in acute myeloid leukemia (AML) patients about to undergo a stem cell transplant can help predict who will have their disease recur, according to a new study by researchers at the US National Heart, Lung, and Blood Institute…
Astellas and BMT CTN Announce Topline Results from Phase 3 MORPHO Trial of Gilteritinib
TOKYO and ROCKVILLE, Md., March 9, 2023 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) today announced topline results from the Phase 3 MORPHO clinical trial evaluating gilteritinib as a maintenance therapy following…
MD Anderson Research Highlights for March 8,
HOUSTON ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments include…
DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant
Importance: Preventing relapse for adults with acute myeloid leukemia (AML) in first remission is the most common indication for allogeneic hematopoietic cell transplant. The presence of AML measurable residual disease (MRD) has been associated with higher relapse rates, but testing is not standardized. Objective: To determine whether DNA sequencing to…
Blood test identifies acute myeloid leukemia patients at greater risk for relapse after bone marrow transplant
News Release Tuesday, March 7, 2023 A small portion of adults in remission from a deadly blood cancer had persisting mutations that were detected, which predicted their risk of death from having the cancer return. Researchers at the National Institutes of Health show the benefits of screening adult patients in remission from acute…
Diagnosis of Second Primary Malignancies Associated With Prolonged Survival Among Patients With MM
Incidence of certain second primary malignancies (SPMs) were associated with increased overall survival (OS) among patients with multiple myeloma (MM), according to abstract findings presented at the 64th American Society of Hematology Meeting and Exposition.1 There is significant literature regarding the incidence of SPMs in patients with MM, in which…
Mutated Cohesin Throws DNA Splicing out of Whack, Resulting in Cancer
The protein complex cohesin is fundamental to the cell division process, as it holds sister chromatids tightly together in a ringlike structure before a cell physically splits. But now researchers at the National Cancer Institute (NCI) have uncovered that the protein complex has another function, too—one that can answer questions…
Actinium Pharma to Discuss Positive Results from the Pivotal Phase 3 SIERRA Trial of Iomab-B By Investing.com
Actinium Pharmaceuticals (NYSE:), Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that it will host a key opinion leader (KOL) webinar at 8 a.m. EST on Tuesday, February 28, 2023, to discuss the results from the recently completed pivotal Phase…
Priothera cleared to begin Japanese arm of pivotal Phase 3 study with mocravimod in patients with Acute Myeloid Leukemia undergoing allogeneic Hematopoietic Cell Transplant
Mocravimod is the only S1PR modulator being developed as an adjunctive and maintenance treatment for blood cancers Dublin, Ireland – February 27th, 2023 – Priothera, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound mocravimod, today announced that it received clearance from the Pharmaceuticals and Medical Devices…
Priothera cleared to begin Japanese arm of pivotal Phase 3
Mocravimod is the only S1PR modulator being developed as an adjunctive and maintenance treatment for blood cancers Dublin, Ireland – February 27th, 2023 – Priothera, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound mocravimod, today announced that it received clearance from the Pharmaceuticals and Medical Devices…
DLBCL therapeutic strategies and gene-oriented treatment
Background Lymphoma is a group of heterogeneous hematological malignancies, which are classified into Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL). Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive NHL. DLBCL can be divided into germinal center B-cell-like (GCB) subgroup and non-GCB subgroup according to the origin of cells….
INTELLIA THERAPEUTICS, INC. Management’s Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)
Our management’s discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements included in this Annual Report on Form 10-K, which have been prepared by us in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and…
New promising targeted drug for a rare leukemia
Targeted drugs have been developed to supplement chemotherapy in the treatment of cancer. These drugs only affect cancer cells, leaving healthy cells alone. Venetoclax is a new targeted therapy option for the treatment of acute myeloid leukemia (AML). It was recently granted marketing authorization in Finland. Venetoclax works by sensitizing…
Akari Therapeutics Announces Presentation of a Case Study from Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA as a Late-Breaker at The Transplantation & Cellular Therapy Tandem Meetings
NEW YORK and LONDON, Feb. 21, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the late-breaker presentation of a patient case study from the Phase 3 Part A clinical trial of nomacopan in pediatric hematopoietic…
NK Cell Therapy Pipeline Analysis Demonstrates Novel 100+ Therapies at the Horizon Expected to Transform the Treatment Paradigm
PRESS RELEASE Published February 21, 2023 DelveInsight’s, “NK Cell Therapy Pipeline Insight, 2023,” report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in the NK Cell Therapy pipeline landscape. It covers the NK Cell Therapy pipeline drug profiles, including NK Cell Therapy clinical trials and nonclinical stage products….
Early Data for Orca-T Cellular Therapy Provides Basis for Phase 3 Study in AML
The use of the precision cellular therapy Orca-T demonstrated promising efficacy effects at a median follow-up of 1 year in patients with acute leukemia or high-risk myelodysplastic syndrome (MDS) in an early analysis of a phase 1b and 2 study that have yet to be reported, according to data presented…
Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia
– Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical significance (p-value of <0.0001), 22% of patients achieved dCR in the Iomab-B arm compared to 0% in the control arm – In patients achieving 6-month dCR with Iomab-b,…
Pfizer Announces Positive TALZENNA and XTANDI Combination Data from Phase 3 TALAPRO-2 Study
NEW YORK – Pfizer (NYSE: PFE) announced today positive results from the Phase 3 TALAPRO-2 study of TALZENNA (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with XTANDI, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival compared to placebo plus XTANDI in men with metastatic…
GlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML
ROCKVILLE, Md – GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the independent Data Monitoring Committee (DMC) reviewed the interim utility analysis of its Phase 3 study of uproleselan in relapsed/refractory (R/R) acute myeloid leukemia (AML) and recommended the study should continue to the originally planned final overall survival event trigger. ‘We…
Phase 3 Trial for Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia to Continue Until OS Event Trigger
An independent data monitoring committee (IDMC) has recommended that a phase 3 trial (NCT03616470) evaluating uproleselan (GMI-1271) plus chemotherapy for patients with relapsed/refractory acute myeloid leukemia (AML) should continue to the planned overall survival (OS) event trigger.1 The IDMC conducted an interim utility analysis using a very high statistical threshold…